Preliminary design of an auxiliary power unit for the space shuttle. Volume 4: Selected system supporting studies

Selected system supporting analyses in conjunction with the preliminary design of an auxiliary power unit (APU) for the space shuttle are presented. Both steady state and transient auxiliary power unit performance, based on digital computer programs, were examined. The selected APU provides up to 400 horsepower out of the gearbox, weighs 227 pounds, and requires 2 pounds per shaft horsepower hour of propellants

Preliminary design of an auxiliary power unit for the space shuttle. Volume 5: Selected system cycle performance data

Detailed cycle steady-state performance data are presented for the final auxiliary power unit (APU) system configuration. The selection configuration is a hydrogen-oxygen APU incorporating a recuperator to utilize the exhaust energy and using the cycle hydrogen flow as a means of cooling the component heat loads. The data are given in the form of computer printouts and provide the following: (1) verification of the adequacy of the design to meet the problem statement for steady-state performance; (2) overall system performance data for the vehicle system analyst to determine propellant consumption and hydraulic fluid temperature as a function for varying mission profiles, propellant inlet conditions, etc.; and (3) detailed component performance and cycle state point data to show what is happening in the cycle as a function of the external forcing functions

Study of the thermal processes for man-in- space

Heat transfer mechanism for cooling human body in spacecraft cabins and extravehicular pressurized suit

Preliminary design of an auxiliary power unit for the space shuttle. Volume 2: Component and system configuration screening analysis

The auxiliary power unit (APU) for the space shuttle is required to provide hydraulic and electrical power on board the booster and orbiter vehicles. Five systems and their associated components, which utilize hot gas turbines to supply horsepower at gearbox output pads, were studied. Hydrogen-oxygen and storable propellants were considered for the hot gas supply. All APU's were required to be self contained with respect to dissipating internally generated heat. These five systems were evaluated relative to a consistent criteria. The system supplied with high pressure gaseous hydrogen and oxygen was recommended as the best approach. It included a two-stage pressure-compounded partial-admission turbine, a propellant conditioning system with recuperation, a control system, and a gearbox. The gearbox output used was 240 HP. At the close of the study a 400 HP level was considered more appropriate for meeting the prime shuttle vehicle needs, and an in-depth analysis of the system at the 400 HP output level was recommended

How valid are assessments of conception probability in ovulatory cycle research? Evaluations, recommendations, and theoretical implications

Over the past two decades, a large literature examining psychological changes across women's ovulatory cycles has accumulated, emphasizing comparisons between fertile and non-fertile phases of the cycle. While some studies have verified ovulation using luteinizing hormone (LH) tests, counting methods – assessments of conception probability based on counting forward from actual or retrospectively recalled onset of last menses, or backward from actual or anticipated onset of next menses – are more common. The validity of these methods remains largely unexplored. Based on published data on the distributions of the lengths of follicular and luteal phases, we created a sample of 58,000+ simulated cycles. We used the sample to assess the validity of counting methods. Aside from methods that count backward from a confirmed onset of next menses, validities are modest, generally ranging from about .40–.55. We offer power estimates and make recommendations for future work. We also discuss implications for interpreting past research

Face, body and speech cues independently predict judgments of attractiveness

Research on human attraction frequently makes use of single-modality stimuli such as neutral-expression facial photographs as proxy indicators of an individual’s attractiveness. However, we know little about how judgments of these single-modality stimuli correspond to judgments of stimuli that incorporate multi-modal cues of face, body and speech. In the present study, ratings of attractiveness judged from videos of participants introducing themselves were independently predicted by judgments of the participant’s facial attractiveness (a neutral-expression facial photograph masked to conceal the hairstyle), body attractiveness (a photograph of the upper body), and speech attractiveness (the soundtrack to the video). We also found that ratings of the face, body and speech were positively related to each other. Our results support the assumption that the single-modality stimuli used in much attractiveness research are valid proxy indicators of overall attractiveness in ecologically valid contexts, and complement literature showing cross-modality concordance of trait attractiveness, but also recommend that research relying on assessments of individual attractiveness take account of both visual and vocal attractiveness where possible

How valid are assessments of conception probability in ovulatory cycle research? Evaluations, recommendations, and theoretical implications

Over the past two decades, a large literature examining psychological changes across women's ovulatory cycles has accumulated, emphasizing comparisons between fertile and non-fertile phases of the cycle. While some studies have verified ovulation using luteinizing hormone (LH) tests, counting methods -assessments of conception probability based on counting forward from actual or retrospectively recalled onset of last menses, or backward from actual or anticipated onset of next menses -are more common. The validity of these methods remains largely unexplored. Based on published data on the distributions of the lengths of follicular and luteal phases, we created a sample of 58,000+ simulated cycles. We used the sample to assess the validity of counting methods. Aside from methods that count backward from a confirmed onset of next menses, validities are modest, generally ranging from about .40-.55. We offer power estimates and make recommendations for future work. We also discuss implications for interpreting past research

EMBRACE: Phase 3/4, Randomized, 52-Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

OBJECTIVE: Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in Phase 2 and 3 belimumab trials was not reflective of the racial distribution observed in the lupus population. This study assessed efficacy and safety of intravenous (IV) belimumab plus standard therapy in patients of self-identified black race. METHODS: EMBRACE (GSK Study BEL115471; NCT01632241): 52-week multicenter, double-blind (DB), placebo-controlled trial in adults of self-identified black race with active SLE, receiving monthly belimumab 10 mg/kg IV, or placebo, plus standard therapy. The optional 26-week open-label extension phase included patients who completed the DB phase. The primary endpoint was SLE Responder Index response rate at Week 52 with modified proteinuria scoring adapted from the SLEDAI-2K (SRI-S2K). Key secondary endpoints included: Week 52 SRI response rate, time to first severe flare, and reductions in prednisone dose. RESULTS: The modified intention-to-treat population comprised 448 patients (96.9% female; mean [standard deviation] age: 38.8 [11.42] years). The primary endpoint (SRI-S2K response rate at Week 52) was not achieved (belimumab 48.7%, placebo 41.6%; p=0.1068); however, numerical improvements favoring belimumab were observed, especially in patients with high baseline disease activity or renal manifestations. The safety profile of belimumab was generally consistent with previous SLE trials. Adverse events were the primary reason for DB phase withdrawals (belimumab 5.4%; placebo 6.7%). CONCLUSIONS: The primary endpoint of this study was not achieved, but improvement with belimumab versus placebo was observed, suggesting that belimumab remains a suitable treatment option for SLE management in patients of Black African ancestry